Quick answer: Compounded tirzepatide is tirzepatide, the active ingredient in Zepbound and Mounjaro, prepared by a compounding pharmacy for an individual patient's prescription. It is not FDA-approved: the FDA does not review compounded drugs for safety, effectiveness or quality, and it was not tested in Zepbound's trials. Since the FDA declared the tirzepatide shortage over (confirmed Dec 19, 2024), pharmacies may no longer make copies of the brand, and state-licensed 503A pharmacies may compound it only for a documented patient-specific need. Telehealth providers list it at about $125 to $432 a month all-in (checked Oct 20, 2026).
- Oct 8, 2026: FDA classified a nationwide Class II recall of compounded tirzepatide 18 mg/mL multi-dose vials from Apothecary Pharma (22 vials, "lack of assurance of sterility"; recall D-0036-2027, started by the firm Sep 24). (FDA Enforcement Report)
- Jul 1, 2026: The Medicare GLP-1 Bridge began: eligible Part D members pay $50 a month for Zepbound (KwikPen), Wegovy or Foundayo through Dec 31, 2027. Compounded tirzepatide is not on the list. (Medicare.gov)
- Jun 26, 2026: FDA extended comments on its 503B bulks-list proposal to Jul 30, 2026. No final decision has been published. (Federal Register)
- May 31, 2026: FDA had received more than 730 adverse event reports tied to compounded tirzepatide (figure on an FDA page current as of Oct 1, 2026). (FDA)
- Apr 30, 2026: FDA proposed keeping tirzepatide (with semaglutide and liraglutide) off the 503B bulks list, finding no clinical need for outsourcing facilities to compound it from bulk drug substance. (FDA press release)
- Apr 30, 2026: Lilly scientists published the testing behind that warning in Expert Opinion on Drug Safety; the authors are Lilly employees and Lilly funded the study. (Lilly study (DOI))
- Mar 17, 2026: FDA classified Class II recalls of compounded tirzepatide multi-dose vials from New Life Pharma for lack of assurance of sterility (D-0394-2026 and D-0395-2026). (FDA Enforcement Report)
- Mar 12, 2026: Eli Lilly said its tests of compounded tirzepatide mixed with vitamin B12 found "significant levels of an impurity" from a reaction between the two, and that it had told FDA. This is the manufacturer's claim, not an FDA finding. (Lilly open letter)
Last checked Oct 20, 2026. Each item is from fda.gov, the Federal Register, Medicare.gov or the manufacturer's own statement.
| What it is | Tirzepatide (the active ingredient in Zepbound and Mounjaro) prepared by a compounding pharmacy for an individual prescription |
|---|---|
| FDA-approved? | No. The FDA does not review compounded drugs for safety, effectiveness or quality before they are sold |
| Who makes it | Mostly state-licensed 503A pharmacies, for a specific patient. 503B outsourcing facilities lost FDA's shortage grace period on Mar 19, 2025 |
| Form | Usually a multi-dose vial drawn with an insulin syringe and measured in units; some sellers offer other forms |
| Prescription needed? | Yes, from a licensed prescriber |
| Legal status (2026) | Not banned outright, but limited: since the shortage ended, a pharmacy may not make copies of Zepbound or Mounjaro, so compounding needs a documented patient-specific reason |
| Typical price | About $125 to $432 a month all-in at telehealth providers (checked Oct 20, 2026) |
| Insurance | Generally not covered; Lilly's savings cards do not apply |
What is compounded tirzepatide?
Tirzepatide is a once-weekly injectable medicine that acts on two gut-hormone receptors, GIP and GLP-1. Eli Lilly sells it under two brand names: Zepbound, approved for chronic weight management and for obstructive sleep apnea in adults with obesity, and Mounjaro, approved for type 2 diabetes (Zepbound prescribing information).
Compounded tirzepatide is a version a pharmacy mixes itself, usually as a multi-dose vial, rather than a product Lilly makes. "Compounded" is not the same as "generic": a generic is an FDA-approved copy of a brand, and Drugs@FDA lists no generic tirzepatide, only Lilly's two brands (Drugs@FDA, checked Oct 20, 2026).
What is in the vial depends on the pharmacy. Strength (mg per mL) varies, and some pharmacies add vitamin B12 (cyanocobalamin), B6 (pyridoxine) or niacinamide, or amino acids such as glycine. No FDA-approved tirzepatide contains those additions, and the FDA has not reviewed any compounded combination; FDA's Enforcement Report lists recalls of compounded tirzepatide-niacinamide and tirzepatide-B12 products (FDA), and Lilly has raised an impurity concern about tirzepatide with B12 (see What changed in 2026, above).
Forms. Most compounded tirzepatide is an injection from a multi-dose vial. Some sellers offer tablets or drops; no oral tirzepatide is FDA-approved (Drugs@FDA lists only Lilly's injectable Zepbound and Mounjaro).
Is compounded tirzepatide legal in 2026? (Is it banned?)
Compounded tirzepatide is not banned, but it is far more limited than it was in 2023 and 2024. During the shortage, pharmacies could compound tirzepatide widely. Once a shortage ends, FDA treats the brand as commercially available, and pharmacies may not compound drugs that are "essentially a copy" of it: the same active ingredient, in the same, similar or easily substitutable strength, by the same route. A prescriber's documented determination that a specific patient needs a significant difference (a different strength, say, or no allergy-causing ingredient) can change that (FDA, page current as of Apr 1, 2026).
| Date | What happened | Source |
|---|---|---|
| Oct 2, 2024 | FDA says the tirzepatide injection shortage is resolved. | FDA |
| Dec 19, 2024 | After re-evaluating, FDA confirms the shortage is over and sets wind-down dates for compounders. | FDA |
| Mar 5, 2025 | A federal court (N.D. Tex., Outsourcing Facilities Association v. FDA) denies a preliminary injunction against FDA's decision. FDA's grace period for state-licensed 503A pharmacies, set to run to the later of Feb 18, 2025 or that ruling, then ends. | FDA |
| Mar 19, 2025 | FDA's grace period for 503B outsourcing facilities ends. | FDA |
| Apr 30, 2026 | FDA proposes not to put tirzepatide (or semaglutide or liraglutide) on the 503B bulks list, finding no clinical need for outsourcing facilities to compound it from bulk drug substance. Published in the Federal Register May 1, 2026. | FDA press release |
| Jun 26, 2026 | FDA extends the comment period on that proposal to Jul 30, 2026. | Federal Register |
| Oct 20, 2026 | No final decision on the 503B bulks-list proposal has been published in the Federal Register. It is still a proposal. | Federal Register |
What that means today, as of Oct 20, 2026:
- 503A pharmacies can still compound tirzepatide for an individual patient when the prescriber documents a clinical reason it differs from the brand.
- 503B outsourcing facilities lost FDA's grace period on Mar 19, 2025. Tirzepatide is not on the 503B bulks list or the FDA drug shortage list, and FDA's Apr 30, 2026 proposal would keep it off the bulks list.
- The 503B proposal is not final. Comments closed Jul 30, 2026; FDA says it will consider them before making a final determination (FDA, Apr 30, 2026; Federal Register notice, May 1, 2026).
- State rules also apply. State boards of pharmacy have primary oversight of 503A pharmacies, so a pharmacy must be licensed where it ships.
How much does compounded tirzepatide cost?
| Option | Monthly price | What it covers |
|---|---|---|
| Compounded tirzepatide (not FDA-approved) | $125 to $432 | Every fee the provider requires (membership, visit, medication); the lowest prices need a 6- or 12-month prepay, and some rise with dose |
| Zepbound (FDA-approved), LillyDirect self-pay | $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5 to 15 mg | Medication only, refilled within 45 days; the prescriber visit is extra |
At the telehealth providers in our compounded tirzepatide cost table, compounded tirzepatide runs about $125 to $432 a month all-in at the starting dose (checked Oct 20, 2026). The low end needs a 6- or 12-month prepay, and several providers raise the price as the dose goes up. Zepbound from LillyDirect is $299 to $449 a month for the medication alone (checked Oct 20, 2026).
Provider-by-provider prices, fees and plan lengths are in our compounded tirzepatide cost breakdown and the cheapest compounded tirzepatide online comparison. For Zepbound and Mounjaro by dose, with insurance and savings cards, see tirzepatide cost with and without insurance.
Is compounded tirzepatide FDA-approved?
No. In the FDA's words, "Compounded drugs are not FDA-approved," and the agency "does not verify the safety, effectiveness or quality of compounded drugs before they are marketed" (FDA compounding Q&A). That holds whichever pharmacy makes it and whatever the label or the website says.
Two kinds of compounder matter here (FDA):
- 503A pharmacies are state-licensed pharmacies. Their state board of pharmacy has primary day-to-day oversight; they are not held to the federal manufacturing standard (CGMP).
- 503B outsourcing facilities register with the FDA, are inspected by it on a risk-based schedule and must follow CGMP. You can check a facility on FDA's list of registered outsourcing facilities.
Can you still get compounded tirzepatide?
Yes. Many telehealth providers still prescribe compounded tirzepatide and have it filled by a state-licensed 503A pharmacy. Because the rules now require a patient-specific reason, a legitimate offer looks like a medical service, not a shop. Before you pay, check:
- A licensed prescriber reviews your health history and can say no. Anyone selling tirzepatide with no prescription, or labelled "research use only" or "not for human use", is not a legitimate pharmacy.
- The pharmacy is named and holds a license in your state; look it up on your state board of pharmacy's site. FDA's BeSafeRx explains how to spot an unsafe online pharmacy.
- The vial label will show the strength in mg/mL, a beyond-use date and the pharmacy's name.
- The all-in monthly price at the dose you are likely to reach, including any membership fee, and the refund terms before you prepay.
- No claim that it is a generic, "the same as" the brand, or FDA-approved. All three are false.
Is compounded tirzepatide safe?
There is no FDA safety review of any compounded tirzepatide product, so nobody can call it safe in the way an approved drug is. Here is what the FDA has reported:
- Adverse-event reports. As of May 31, 2026, the FDA had received more than 730 reports of adverse events associated with compounded tirzepatide (and 990 for compounded semaglutide), including reports, some requiring hospitalization, that may be related to dosing errors (FDA's concerns with unapproved GLP-1 drugs, page current as of Oct 1, 2026).
- Dosing errors. A multi-dose vial is measured in syringe units, not milligrams, and the units for a dose depend on the vial's strength.
- Sterility recalls. FDA's Enforcement Report lists Class II recalls of tirzepatide multi-dose vials not made by Lilly for "lack of assurance of sterility" in 2026: D-0394-2026 and D-0395-2026 (classified Mar 17, 2026) and D-0036-2027 (Apothecary Pharma, classified Oct 8, 2026, distributed nationwide). Check it for any lot you have.
- Unapproved sellers. FDA has warned telehealth companies, ingredient distributors and outsourcing facilities over unapproved GLP-1 drugs (FDA).
Side effects. Compounded tirzepatide has not been studied, so its side-effect rates are unknown. The tirzepatide molecule's known risks are listed on the Zepbound label: a boxed warning about thyroid C-cell tumors (do not use with a personal or family history of medullary thyroid cancer or MEN 2), plus pancreatitis, gallbladder problems, low blood sugar with some diabetes medicines, kidney problems from dehydration and serious allergic reactions. The most common are nausea, diarrhea, vomiting, constipation, stomach pain, indigestion and injection-site reactions (Zepbound prescribing information). Report a problem to your prescriber and to FDA MedWatch.
Compounded tirzepatide vs Zepbound and Mounjaro
Zepbound and Mounjaro are the same molecule from the same maker, approved for different uses. Compounded tirzepatide shares the active ingredient and little else:
| Zepbound / Mounjaro (Eli Lilly) | Compounded tirzepatide | |
|---|---|---|
| FDA-approved? | Yes: Zepbound for chronic weight management (and sleep apnea with obesity), Mounjaro for type 2 diabetes | No |
| Studied in clinical trials? | Yes, as the approved products | No; trial results for the brands do not apply to it |
| Who makes it | Eli Lilly, under FDA manufacturing rules | A compounding pharmacy, overseen mainly by its state board (503A) |
| Form | Single-dose pens; Zepbound also in single-dose vials | Usually a multi-dose vial; strength (mg/mL) varies by pharmacy |
| Extra ingredients | Only what the approved label lists | Some add vitamins such as B12 or B6, which no approved tirzepatide product contains |
For the side-by-side in full, including switching, see compounded tirzepatide vs Zepbound.
How is compounded tirzepatide dosed and stored?
Your prescriber sets the dose in milligrams. Because a compounded vial holds a stated number of mg per mL, the syringe reading depends on that strength: units = dose (mg) ÷ strength (mg/mL) × 100 on a U-100 insulin syringe. A 2.5 mg dose is 25 units at 10 mg/mL but 12.5 units at 20 mg/mL. Use the strength printed on your own vial, recheck it at every refill, and use the compounded tirzepatide dosage in units calculator to check the arithmetic. The brand's labelled schedule is in our tirzepatide dosage chart.
Storage: follow the storage directions and beyond-use date on your pharmacy label. Once you first puncture a multi-dose vial, FDA advises discarding it 28 days later, even if medication remains (FDA).
How to get compounded tirzepatide legitimately
The legitimate route is the same at every reputable provider:
- Medical intake. You answer a health questionnaire and, depending on the state, have a video or messaging visit. Expect questions about thyroid cancer history, pancreatitis, pregnancy and other medicines.
- A licensed prescriber decides. If tirzepatide suits you and there is a documented reason a compounded version fits better than the brand, they write a prescription. If not, they should say so, and may offer Zepbound instead.
- A named 503A pharmacy fills it for you, and ships a labelled vial with syringes and instructions in units.
- Follow-up. Dose changes go through the prescriber, never a self-adjustment.
If you would rather use the FDA-approved product, Zepbound is sold self-pay through LillyDirect with a prescription. Compare both routes on price in the tirzepatide price table.
Compounded tirzepatide FAQ
Is compounded tirzepatide banned in 2026?
No, it is not banned outright, but it is restricted: since FDA declared the shortage over (confirmed Dec 19, 2024), pharmacies may not make copies of Zepbound or Mounjaro, so a 503A pharmacy needs a patient-specific reason documented by the prescriber. FDA has also proposed (Apr 30, 2026) keeping tirzepatide off the 503B bulks list; that proposal was not final as of Oct 20, 2026.
Is compounded tirzepatide still available?
Yes. Telehealth providers still prescribe it and state-licensed 503A pharmacies still fill it, under the narrower rules that followed the end of the shortage.
Is compounded tirzepatide going away?
For 503B outsourcing facilities, FDA's shortage grace period ended Mar 19, 2025, and its Apr 30, 2026 proposal would keep them from compounding it from bulk drug substance. For 503A pharmacies, FDA has announced no further change as of Oct 20, 2026.
Is compounded tirzepatide the same as Zepbound?
No. It has the same active ingredient, but it is not FDA-approved, was not tested in Zepbound's trials, and can differ in strength, form and added ingredients.
Is compounded tirzepatide as effective as Zepbound?
No one knows: compounded tirzepatide has not been studied in clinical trials, so Zepbound's trial results do not apply to it.
What is compounded tirzepatide mixed with?
Some compounding pharmacies add vitamins such as B12 or B6. No FDA-approved tirzepatide product contains them, and the FDA has not reviewed those combinations.
Is compounded tirzepatide a generic?
No. The FDA has approved no generic tirzepatide; the only approved tirzepatide products are Lilly's Zepbound and Mounjaro, and a compounded drug is not a generic.
Does insurance cover compounded tirzepatide?
Generally no, and Lilly's savings cards do not apply to it. Some people use FSA or HSA funds for a prescribed medication; check with your plan administrator.
How long is compounded tirzepatide good for in the fridge?
Follow the storage and beyond-use date on your pharmacy label. Once a multi-dose vial is opened, FDA advises discarding it 28 days after first use, even if medication remains.
What is the brand name for tirzepatide injections?
Zepbound (for chronic weight management and obstructive sleep apnea with obesity) and Mounjaro (for type 2 diabetes), both made by Eli Lilly.
What are the key differences between tirzepatide compound and Zepbound?
Zepbound is Eli Lilly's FDA-approved tirzepatide, made under federal manufacturing rules, tested in clinical trials and sold in single-dose pens or vials. Compounded tirzepatide shares the active ingredient but is not FDA-approved, has no trials of its own, usually comes in a multi-dose vial whose strength varies by pharmacy, and may contain added vitamins.
How to inject tirzepatide?
Under the skin once a week, in the stomach, thigh or upper arm, rotating the site each week, at any time of day with or without meals, per the Zepbound instructions. A compounded vial is drawn with an insulin syringe, so the units depend on the vial's strength: follow your prescriber's and pharmacy's directions exactly.
What class of medication does tirzepatide belong to?
Tirzepatide is a GIP receptor and GLP-1 receptor agonist (a dual GIP/GLP-1 agonist), taken as a once-weekly injection. Semaglutide, by contrast, acts on the GLP-1 receptor only.
Is it safe to take tirzepatide and semaglutide together?
No such combination is approved: Lilly's Zepbound information says not to use it with other tirzepatide products or with any GLP-1 receptor agonist medicine, which includes semaglutide (Ozempic, Wegovy and compounded versions).
What should I avoid while taking tirzepatide?
Per the Zepbound label: other tirzepatide or GLP-1 medicines at the same time, and use at all with a personal or family history of medullary thyroid cancer or MEN 2. Tell your prescriber if you take insulin or a sulfonylurea (low blood sugar risk) or birth control pills, which may work less well after starting and after each dose increase.
Is tirzepatide the same as Ozempic?
No. Ozempic is semaglutide from Novo Nordisk, approved for type 2 diabetes; tirzepatide is a different molecule from Eli Lilly, sold as Mounjaro and Zepbound, and compounded versions of either are not FDA-approved.
Do I need a prescription for compounded tirzepatide?
Yes. A 503A pharmacy compounds it only for a prescription written for you; a site that sells tirzepatide without one, or as "research use only", is not a legitimate pharmacy.
Sources and references
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of Apr 1, 2026; checked Oct 20, 2026)
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of Oct 1, 2026; checked Oct 20, 2026)
- FDA: Compounding and the FDA, questions and answers (checked Oct 20, 2026)
- FDA press release: FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (Apr 30, 2026)
- Federal Register 2026-08552: List of bulk drug substances for which there is a clinical need under section 503B (May 1, 2026) and extension of comment period, 2026-12937 (Jun 26, 2026)
- FDA Enforcement Report (recalls D-0394-2026 and D-0395-2026; checked Oct 20, 2026)
- Drugs@FDA: tirzepatide approvals are NDA 217806 (Zepbound) and NDA 215866 (Mounjaro) (checked Oct 20, 2026)
- FDA: Registered outsourcing facilities and FDA BeSafeRx
- Zepbound (tirzepatide) prescribing information, DailyMed
- LillyDirect: Zepbound self-pay prices (checked Oct 20, 2026)
- FDA Enforcement Report: recall D-0036-2027, Apothecary Pharma tirzepatide injection (classified Oct 8, 2026; checked Oct 20, 2026)
- Eli Lilly: open letter on tirzepatide compounded with vitamin B12 (Mar 12, 2026) and Jordan B et al. A novel, widespread impurity in mass-compounded tirzepatide/B12 products. Expert Opin Drug Saf 2026;25(5):837-845 (Lilly-funded; manufacturer's own testing)
- Medicare.gov: Medicare GLP-1 Bridge (checked Oct 20, 2026)
Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. Nouri is not affiliated with Eli Lilly. Nouri is a publisher; it does not prescribe or sell any medication. Compounded tirzepatide is not FDA-approved, has not been evaluated by the FDA for safety, effectiveness or quality, and is not therapeutically equivalent to Zepbound or Mounjaro. Not medical or legal advice: a licensed prescriber decides whether any tirzepatide fits you.
Disclosure: Nouri may earn a commission when you sign up with some of the providers we link to. It doesn't change what you pay or how we rank providers. Full disclosure.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Nouri is an independent publisher: it does not prescribe, review patient assessments, or sell medication. Talk to a licensed clinician before starting or changing any medication or treatment.
Compare licensed GLP-1 providers
Published cash prices side by side, with the month we checked them and a link to each provider's own site. Nouri doesn't prescribe or sell medication.